PT  - JOURNAL ARTICLE
AU  - Cecchini, Michael
AU  - Sznol, Mario
AU  - Seropian, Stuart
TI  - Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant
AID  - 10.1186/s40425-015-0054-4
DP  - 2015 Dec 01
TA  - Journal for ImmunoTherapy of Cancer
PG  - 10
VI  - 3
IP  - 1
4099  - http://jitc.bmj.com/content/3/1/10.short
4100  - http://jitc.bmj.com/content/3/1/10.full
SO  - J Immunother Cancer2015 Dec 01; 3
AB  - Metastatic melanoma is frequently treated with immune activating therapy, which poses a theoretical risk of inducing graft versus host disease (GVHD) in those who have received allogeneic stem cell transplantation. The literature reporting the safety of immunotherapy in post transplant patients is limited. We report two patients with metastatic melanoma who received treatment with immunotherapy after allogeneic stem cell transplantation that did not result in GVHD.Abbreviations:GVHDGraft versus host diseaseIL-2Interleukin-2CTLA-4Cytotoxic T-lymphocyte associated proteinPD-1Programmed cell deathPD-L1Programmed death-ligand 1ASCTAllogeneic stem cell transplantsCMLChronic Myeloid LeukemiaCTComputed TomographyGKRSGamma knife radiosurgery